Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
Maintaining Sandoz 2023 guidance
Expected, barring unforeseen events; growth vs. PY in cc
2023
Mid-term
FINANCIAL PROFILE
Sales expected to grow mid single digit
Core Oplnc expected to decline low double digit reflecting required stand-up investments
to transition Sandoz to a separate company and continued inflationary pressures
Sales expected to grow mid single digit
Core Oplnc margin expected to expand to mid 20s, continuously progressing from
the low 2023 base driven by continued sales growth and operational efficiencies
Key assumptions:
Sandoz spin-off completed in early Q4 2023
After completion of planned Sandoz spin-off, Core Oplnc guidance will be expressed in terms of core EBITDA. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial
Report.
23 Investor Relations | Q2 2023 Results
ā NOVARTIS | Reimagining MedicineView entire presentation